American Century Companies Inc. Trims Holdings in Illumina, Inc. $ILMN

Key Points

• American Century Companies Inc. reduced its stake in Illumina, Inc. by 15.8%, holding approximately 191,003 shares valued at $15.15 million after selling 35,849 shares in the first quarter.
• Illumina reported quarterly earnings of $1.19 per share, exceeding estimates, but faced a 4.8% decline in year-over-year revenue, totaling $1.06 billion.
• Wall Street analysts have mixed opinions on Illumina, with seven analysts rating it as a Buy and others adjusting their target prices, reflecting varying confidence in the stock's performance.

American Century Companies Inc. reduced its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 15.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,003 shares of the life sciences company's stock after selling 35,849 shares during the period. American Century Companies Inc. owned about 0.12% of Illumina worth $15,154,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. MML Investors Services LLC boosted its holdings in Illumina by 10.8% during the fourth quarter. MML Investors Services LLC now owns 25,888 shares of the life sciences company's stock worth $3,459,000 after buying an additional 2,515 shares in the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Illumina by 10.1% during the fourth quarter. Integrated Wealth Concepts LLC now owns 3,291 shares of the life sciences company's stock valued at $440,000 after purchasing an additional 301 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Illumina during the fourth quarter valued at $11,301,000. Oxford Asset Management LLP purchased a new position in Illumina during the fourth quarter valued at $308,000. Finally, Northern Trust Corp lifted its holdings in Illumina by 26.9% during the fourth quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after purchasing an additional 349,878 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 0.8%

ILMN stock traded up $0.79 during trading on Friday, reaching $99.96. 1,009,106 shares of the stock were exchanged, compared to its average volume of 1,732,308. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $99.10 and a 200-day moving average price of $88.56. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a market capitalization of $15.36 billion, a price-to-earnings ratio of 12.65, a P/E/G ratio of 2.25 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned $0.36 earnings per share. Illumina's quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Evercore ISI increased their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Robert W. Baird raised their price target on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Stephens set a $110.00 price target on shares of Illumina and gave the stock an "overweight" rating in a research note on Monday, August 4th. Finally, Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research note on Friday, July 11th. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Illumina presently has a consensus rating of "Hold" and an average price target of $123.17.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.